Yelena Y. Janjigian, MD, has been appointed chief of the Gastrointestinal Medical Oncology Service in the Division of Solid Tumor Oncology, Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. She will succeed Leonard Saltz, MD, who had held this position for 5 years. Saltz will assume the position of executive director for clincal value and sustainability.
Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD, has been appointed chief of the Gastrointestinal Medical Oncology Service in the Division of Solid Tumor Oncology, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK) in New York. She will succeed Leonard Saltz, MD, who had held this position for 5 years. Saltz will assume the position of executive director for clincal value and sustainability.
Janjigian has been a part of the faculty at MSK since 2009, serving in the Gastrointestinal Medical Oncology Service, with a focus on improving treatment outcomes for patients with esophageal and gastric cancers.
An international expert in cancers of the esophagus and stomach, Janjigian is currently leading several studies that could impact the standard of care for cancers in these fields. For example, she is the lead investigator for the ongoing phase III CheckMate 649 trial of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced gastric or gastroesophageal junction cancer compared with nivolumab and chemotherapy or chemotherapy alone (NCT02872116). She focuses her research on new treatment strategies, with an emphasis on defining therapeutically relevant molecular characteristics of tumors in the gastrointestinal tract.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Tumor Treating Fields Show Significant Survival Benefit in Pancreatic Cancer
December 2nd 2024The PANOVA-3 trial demonstrated a significant 2-month overall survival improvement when adding tumor treating fields to gemcitabine and nab-paclitaxel for patients with locally advanced pancreatic adenocarcinoma.
Read More